IG
Inno Gene S.A. Stock: price and insider trades · Poland
Inno Gene S.A.: what insiders have been doing
Only a handful of insider records exist for Inno Gene S.A., the last one from 18 May 2026, too few to describe a trend. These figures are compiled from regulatory filings published by KNF. They describe what insiders did and are not a recommendation.
Insider Decl.
1
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
n/a
n/a
Fundamental score
Ranked 26,634 of 26,897 companies
6.8
score / 100
Value1
Quality13
FCF yld-89%
Earn yld-169%
EV/EBITDA·
ROE-296%
Gross mgn22%
Net mgn-35%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2024FY ended December 2024 · cache
€0.44
Analyst consensus
Income statement
Revenue€138.8M
Gross profit€30.7M22% margin
EBITDA-€37.5M-27% margin
Net income-€49.0M-53.4% margin
Valuation
Beta0.01
Balance sheet & cash
Market cap€29.0M
Total debt€29.1M
Free Cash Flow-€26.0M
Debt / Equity9373%
Profitability & ownership
ROE-295.5%
ROA-6.1%
% insiders60.4%
% institutions2.1%
Last declaration on 18 May 2026
Declarations1 total
- ●Executives0KNF
1 of 1 declaration
About Inno Gene S.A.
Inno Gene S.A. is a company specialized in the healthcare and pharmaceutical sector. It is listed on the XWAR market.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
